Brentuximab vedotin - CAS 914088-09-8

Brentuximab vedotin - CAS 914088-09-8 Catalog number: BADC-00031

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Brentuximab vedotin is an antibody-drug conjungate (ADC) used for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin acts through targeting tumor cells with CD30 antigen expressed in.

Category
ADCs Cytotoxin with Linkers
Product Name
Brentuximab vedotin
CAS
914088-09-8
Catalog Number
BADC-00031

Ordering Information

Catalog Number Size Price Quantity
BADC-00031 -- $--
Inquiry
Description
Brentuximab vedotin is an antibody-drug conjungate (ADC) used for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin acts through targeting tumor cells with CD30 antigen expressed in.
Synonyms
SGN-35; previously cAC10-vcMMAE; SGN 35; SGN35
In Vitro
In an in vitro model mimicking GCT of heterogeneous histology, Brentuximab vedotin abrogates cell viability of CD30-positive GCT27 EC line exerting marked time-dependent antiproliferative and pro-apoptotic activity. CD30-negative JAR cultured alone barely responds to brentuximab vedotin, while in coculture with GCT27 brentuximab vedotin induces clear dose-dependent cytotoxicity. Cellular proliferation and cell death are significantly enhanced in CD30-negative JAR cocultured with CD30-positive GCT27 compared to JAR cultured alone in proof of substantial bystander activity of brentuximab vedotin in CD30-negative GCT.
In Vivo
In vivo brentuximab vedotin promoted tumor regression and prolonged survival of mice bearing previously reported UM-PEL-1 tumors as well as UM-PEL-3 tumors derived from a newly established and characterized Kaposi's sarcoma-associated herpesvirus- and Epstein-Barr virus-positive PEL cell line.
Clinical Trial Information
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT01940796Graft-vs-Host DiseasePhase 12018-07-26Massachusetts General HospitalTerminated (Toxicity)
NCT03187210LymphomaPhase 1, Phase 22021-08-05University Hospital Inselspital, BerneRecruiting
NCT02227433Hodgkin LymphomaPhase 22020-12-22Fondazione Italiana Linfomi ONLUSCompleted
NCT03222492Diffuse Cutaneous Systemic SclerosisPhase 1,Phase 22021-04-12National Institute of Allergy and Infectious Diseases (NIAID)Recruiting
NCT03587844Mycosis FungoidesPhase 22021-11-04Memorial Sloan Kettering Cancer CenterRecruiting
Application
the treatment of Hodgkin lymphoma and ALCL
Shipping
Room temperature
Current Developer
Seattle Genetics; Takeda Pharmaceutical

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Services

Products

Resource

Send Inquiry

Verification code
Inquiry Basket